CURIGLIANO, GIUSEPPE
CURIGLIANO, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
2026 G. Mazzoli, L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Fotia, M. De Monte, F. Ligorio, F. Jacobs, G. Armani, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, A.C. Schianca, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, G. the PALMARES-2 study, C. Vernieri
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale
2026 M. Del Re, E. Inglese, E. Bria, E.J. Blok, R.H.J. Mathijssen, G. Curigliano, R. Danesi
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study
2026 C. Valenza, J.D. Etessami, M. Milano, N. Papadopoulos, M. Alvino, G. Antonarelli, N. Bianco, C. Sangalli, D. Trapani, G. Pravettoni, E. Omodeo Salè, R. Passerini, M. Colleoni, E. Munzone, G. Curigliano
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer
2026 A. Brufsky, R.M. Layman, X. Liu, B. Li, L. Mcroy, A. Cohen, M. Estevez, P. Cottu, M. Thill, G. Curigliano, H.S. Rugo
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025
2026 E. Nicolò, F. Bertucci, H. Boussen, G. Curigliano, V. Fraser, L. Gerratana, S. Krishnamurthy, H.T. Le‐petross, B. Lim, F. Lynce, A. Lucci, S. Lucotti, M. Manai, S. Merajver, N. Missal, A. Nasrazadani, A. Soliman, C. Valenza, C. Van Berckelaer, S. Van Laere, W.A. Woodward, M. Cristofanilli, G. Devi
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
2026 C. Biagioni, D. Fimereli, A. Irrthum, A. Guerrero-Zotano, M. Piccart, D. Cameron, C. Caballero, A. Raimbault, D. Martins-Branco, D. Romagnoli, E. Agostinetto, D. Venet, A. Llinas-Bertran, J.A. Seoane, G. Zoppoli, A. Vivancos, A. Vingiani, M. Oliveira, G. Curigliano, T. Crestani, C. Sotiriou, E. Nili Gal-Yam, F.S. Hilbers, P. Aftimos, M. Benelli
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Advancing oncology innovation under persistent constraints
2026 D. Trapani, G. Curigliano
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
2026 C. De Angelis, D. De Biase, L. Gerratana, G. Arpino, G. Bianchini, I. Castellano, G. Curigliano, L. Del Mastro, A. Fabi, N. Fusco, A. Gennari, V. Guarneri, C. Zamagni, A. Zambelli, U. Malapelle, F. Puglisi
Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer
2026 C. Corti, T. Li, A.R. Martin, M.E. Hughes, T. Parker, T.S. Duporte, G. Curigliano, T.A. King, E.A. Mittendorf, N.U. Lin, N. Tayob, S.M. Tolaney
Locally advanced breast cancers: the EUSOMA experience
2026 P. Van Dam, M. Tomatis, A. Ponti, L. Marotti, J. Verhaegen, C. Aristei, M.J. Cardoso, K.L. Cheung, G. Curigliano, J. De Vries, D. Santini, F. Sardanelli, I.T. Rubio, C.A.P. Anghelone, A. Baldissera, E. Benozzi, M. Berlière, B. Bussels, K. Cagossi, N. Caldana, F. Caruso, C. Cedolini, F. Corsi, E. Despierre, L. Despini, B. Dullens, A.J. Esgueva, G. Fogazzi, L. Fortunato, J.L. Fougo, D. Generali, A. Gennari, M. Ghilli, P.F. Gouveia, S. Grossi, J. Heiman, R. Helfgott, A. Huscher, H. Loobuyck, M.E. Edith Lüthy, S. Marquette, G. Melucci, F. Piacentini, A. Prové, F. Riccardi, K. Rogowski, G. Romanucci, L. Rossi, C.R. Santos, S. Scomersi, G. Staelens, M. Vassilieff, V. Venizelos, P. Veronesi, C. Zamagni, D. Zanoni
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer
2026 K.L. Jhaveri, N.M. Iyengar, N.C. Turner, H.S. Rugo, J. O'Shaughnessy, C.H. Barrios, G. Curigliano, F. André, S. Im, M.D. Goncalves, M.E. Lacouture, P.A. Fasching, R. Leung
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
2026 D. Ciardiello, L. Boscolo Bielo, S. Napolitano, E. Martinelli, T. Troiani, E. Cioli, T.P. Latiano, E. Maiello, P. Parente, A. Avallone, A. De Stefano, R. Bordonaro, A.E. Russo, C. Lotesoriere, S. Vallarelli, S. Pisconti, C. Nisi, E. Tamburini, M.G. Viola, S. Lonardi, C. Cremolini, D. Iacono, P. Tagliaferri, F. Pietrantonio, G. Tortora, G. Rosati, M.G. Zampino, G. Curigliano, A. Febbraro, N. Normanno, F. De Vita, N. Fazio, F. Ciardiello, G. Martini
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study
2026 N. Bianco, C. Valenza, M. Milano, R. Multinu, E. Battaiotto, M. Cavallone, G. Malvezzi, D. Trapani, P. Della Vigna, G. Bonomo, G.M. Varano, D. Maiettini, M.G. Pitoni, C. Sangalli, E. Munzone, G. Curigliano, M.A. Colleoni, F. Orsi
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
2026 B. Besse, V. Subbiah, G. Curigliano, D.W. Bowles, R.C. Doebele, A.S. Mansfield, C.S. Baik, G. De Lima Lopes, L. Paz-Ares, M.H. Taylor, D.S.W. Tan, G. Alonso, S.M. Gadgeel, G.P. Kalemkerian, S.I. Ou, A.J. Van Der Wekken, C.R. Becerra, M. Evangelist, F. Griesinger, S.V. Liu, Y. Lou, J. Mazières, J.M. Melear, M. Narang, A. Saxena, M. Thomas, S. Wang, A. Thomassen, D.H. Lee, D. Kim, J.F. Gainor
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
2026 K.L. Jhaveri, P. Neven, M.L. Casalnuovo, S. Kim, E. Tokunaga, P. Aftimos, C. Saura, J. O'Shaughnessy, N. Harbeck, L.A. Carey, G. Curigliano, J. Watanabe, E. Lim, J. Huang, Z. Qingyuan, A. Llombart-Cussac, C. Huang, B. Desai, Y. Limay, X.A. Wang, S. Cao, F.C. Bidard
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study
2026 R. Scafetta, R. Troiano, C. Gullotta, A. Guarino, C. Fiore, L. Sisca, E. Speziale, M. Donato, S. Foderaro, F. Venuti, F.A. Vilardi, V. Ricozzi, M. Iuliani, S. Simonetti, S. Cavaliere, A. Cortellini, A.L. Cesa, A. Botticelli, S. Scagnoli, S. Pisegna, C. Criscitiello, R. Pedersini, C. Sposetti, E. Tiberi, G. D'Auria, M. Vergati, M. Mazzotta, R. Caputo, A. Verrazzo, O. Garrone, F. Domati, C. Piombino, F.S.D. Lisa, L. Filomeno, T. Arcuri, F. Puce, F. Riva, M. Palleschi, M. Sirico, M. Piras, L.S. Stucci, D.D. Lisi, P. Orsaria, A. Grasso, E. Ippolito, S. Ramella, L. Visani, L. Livi, S. Gori, L. Rossi, I. Meattini, B. Tagliaferri, O. Caffo, M.V. Bonomo, I. Portarena, A. Irelli, E. Cretella, C. Porta, G. Bianchini, M.A. Fabbri, U.D. Giorgi, P. Vici, A. Toss, F. Ruatta, M.D. Laurentiis, F. Villa, R. Berardi, M. Minelli, V. Altomare, C. Vernieri, G. Curigliano, A. Chirco, S. D'Alessandro, B. Vincenzi, G. Tonini, D. Santini, F. Pantano
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial
2026 G. Curigliano, J. O'Shaughnessy, F. Bidard, M.L. Casalnuovo, S. Kim, E. Tokunaga, P. Aftimos, C. Saura, L.A. Carey, M. Okera, E. Melo, F. Zagouri, M. Magallanes-Maciel, N. Karadurmus, S. Bahadur, R.M. Speck, X.A. Wang, K. Pradhan, J. Macey, H. Kitchen, S. Fairhurst, J. Miller, K.L. Jhaveri, N. Harbeck
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
2026 F. Lynce, C. Valenza, S.M. Niman, F. Bertucci, M. Kai, S. Ryan, E. Troll, R.M. Layman, K.A. Fanucci, A. Giordano, A. Nasrazadani, F. Nakhlis, J. Bellon, L. Warren, C. Block, S. Schumer, A. Lucci, S. Krishnamurthy, D. Trapani, F. Lerebours, F. Dalenc, C. Levy, T. Petit, M. Leheurteur, T. Bachelot, O. Tredan, J.M. Ribeiro, B. Pistilli, P. Zagami, S. Ladoire, L. Lopez Almeida, C. Zemmour, L.A. Carey, S.M. Tolaney, V. Valero, G. Curigliano, M.M. Regan, A. Goncalves, W.A. Woodward